Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication

Abstract

Abstract We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation. Clinicians should carefully monitor the course of DPP‐4 inhibitor‐associated BP even after withdrawal of DPP‐4 inhibitor therapy, especially in very elderly patients.

Keywords

• bullous pemphigoid
• dipeptidyl peptidase‐4 inhibitor
• type 2 diabetes